Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Isocitrate dehydrogenase ( ) mutations arise early in gliomas and are associated with a defined neurodevelopmental cancer cell hierarchy. However, how mutant IDH contributes to this hierarchy and whether this interaction promotes gliomagenesis remain unclear. We captured the dynamics of IDH-mutant glioma initiation in genetically engineered mice through time-resolved, single-cell genomics. Mutant IDH activates and induces lineage switching of neural progenitor cells (NPCs). These actions expand oligodendrocyte precursor cells, the predominant cell-of-origin for these tumors, at the expense of interneurons. Lineage switching is mediated by promoter hypermethylation and silencing of , a homeobox gene required for neurogenesis. Critically, ablation recapitulates NPC fate reprogramming by mutant IDH. We provide a new model of neural cell fate control by oncogenes and insights into the developmental origins of glioma.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363803PMC
http://dx.doi.org/10.1101/2025.08.12.667486DOI Listing

Publication Analysis

Top Keywords

mutant idh
16
neural progenitor
8
cell fate
8
lineage switching
8
mutant
4
idh silences
4
silences gsx2
4
gsx2 reprogram
4
reprogram neural
4
progenitor cell
4

Similar Publications

Isocitrate dehydrogenase mutation and microenvironment in gliomas: do immunotherapy approaches matter?

Curr Opin Neurol

September 2025

Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ).

Purpose Of Review: Gliomas with mutations in the gene for isocitrate dehydrogenase (IDH) display a unique immune microenvironment that is distinct from IDH-wildtype gliomas. This unique immune microenvironment is shaped by 2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH. These features provide an opportunity to develop and test targeted immunotherapies for IDH-mutant gliomas.

View Article and Find Full Text PDF

Estimating Health State Utilities for IDH-Mutant Diffuse Glioma.

Pharmacoecon Open

September 2025

Acaster Lloyd Consulting Ltd, Lacon House, 84 Theobalds Rd, London, WC1X 8NL, UK.

Background: Isocitrate dehydrogenase-mutant (mIDH) gliomas are malignant central nervous system tumours. After initial resection, patients with mIDH gliomas with favourable prognosis may live without receiving oncologic treatment for years, but ultimately patients will experience recurrence and require radio- and/or chemotherapy (RT/CT). Cost-utility analyses (CUA) can explore the value of treatments that delay recurrence and initiation of RT/CT.

View Article and Find Full Text PDF

On August 6, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval to vorasidenib (VORANIGO, Servier Pharmaceuticals, LLC) for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 or 2 (IDH1 or IDH2) mutation following surgery including biopsy, sub-total resection, or gross total resection.

View Article and Find Full Text PDF

Objective: Cortical speech mapping using navigated Transcranial Magnetic Stimulation (nTMS) has a variable positive predictive value (PPV) when compared with intraoperative direct electrical stimulation.

Methods: This is a single centre prospective study of all patients undergoing pre-operative nTMS and tractography (frontal aslant tract (FAT) and arcuate fasciculus (AF)) for awake surgery between October 2018 and November 2023. We reviewed operative notes for speech arrest, collected data on demographics, histopathology and pre-/post-operative language assessment.

View Article and Find Full Text PDF

Super-Resolution MR Spectroscopic Imaging via Diffusion Models for Tumor Metabolism Mapping.

J Imaging Inform Med

September 2025

A. A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.

High-resolution magnetic resonance spectroscopic imaging (MRSI) plays a crucial role in characterizing tumor metabolism and guiding clinical decisions for glioma patients. However, due to inherently low metabolite concentrations and signal-to-noise ratio (SNR) limitations, MRSI data are often acquired at low spatial resolution, hindering accurate visualization of tumor heterogeneity and margins. In this study, we propose a novel deep learning framework based on conditional denoising diffusion probabilistic models for super-resolution reconstruction of MRSI, with a particular focus on mutant isocitrate dehydrogenase (IDH) gliomas.

View Article and Find Full Text PDF